Atomwise News

Featured Article
The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications SAN FRANCISCO--(BUSINESS WIRE)--Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics, a clinical stage biotech company, announced today a research collaboration to launch up to 13 small molecule programs...
Read Article